Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone949-297-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$858.29 million
Profitability
Miscellaneous
Employees1,500
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Masimo (NASDAQ:MASI) Frequently Asked Questions
What is Masimo's stock symbol?
Masimo trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo's earnings last quarter?
Masimo Co. (NASDAQ:MASI) issued its quarterly earnings data on Tuesday, February, 26th. The medical equipment provider reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.10. The medical equipment provider earned $223.10 million during the quarter, compared to the consensus estimate of $220.96 million. Masimo had a net margin of 22.55% and a return on equity of 19.53%. Masimo's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.72 earnings per share. View Masimo's Earnings History.
When is Masimo's next earnings date?
What guidance has Masimo issued on next quarter's earnings?
Masimo issued an update on its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share guidance of $3.08-3.08 for the period, compared to the Thomson Reuters consensus estimate of $3.04. The company issued revenue guidance of $912-912 million, compared to the consensus revenue estimate of $909.68 million.
What price target have analysts set for MASI?
5 Wall Street analysts have issued 1-year target prices for Masimo's shares. Their predictions range from $100.00 to $155.00. On average, they expect Masimo's share price to reach $135.40 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price. View Analyst Price Targets for Masimo.
What is the consensus analysts' recommendation for Masimo?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Masimo.
What are Wall Street analysts saying about Masimo stock?
Here are some recent quotes from research analysts about Masimo stock:
- 1. Needham & Company LLC analysts commented, "We hosted investor meetings with Kammerman, this week in the Midwest. We come away from the meetings with a better appreciation of MASI’s growth and margin outlook. We believe that MASI’s business model and product portfolio should enable it to sustain strong and consistent top and bottom line growth. Additionally, we think that the impact of the Philips agreement should cumulatively build as boards with MASI’s Rainbow and other measurements are installed in an increasing portion of Philips’ installed base. And we see several catalysts (detailed below) that could help MASI shares in 2019. Given all of this, we reiterate our Buy rating." (2/1/2019)
- 2. According to Zacks Investment Research, "Masimo outperformed its industry in a year’s time. The company’s key Product revenue segment has been witnessing strong growth in recent times. The company also continues to see strong demand for its SET pulse oximetry products and rainbow platform. Management is optimistic about Masimo’s alliance with Philips. Increased R&D expenses imply greater focus on innovation. Management is also hopeful about receiving FDA clearance for ORi. In fact, the company recently received FDA approval for RD SET sensors with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. A raised guidance for 2018 paints a bright picture. On the flip side, Masimo’s Royalty and Other segment have been sluggish in recent times. Furthermore, the company faces fierce competition from the MedTech bigwigs. The stock is overvalued at the moment." (1/23/2019)
Has Masimo been receiving favorable news coverage?
News headlines about MASI stock have been trending negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Masimo earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of Masimo's key competitors?
Some companies that are related to Masimo include SONOVA HLDG AG/ADR (SONVY), Varian Medical Systems (VAR), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), AxoGen (AXGN), Viewray (VRAY), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Cutera (CUTR), Electrocore (ECOR) and Helius Medical Technologies (HSDT).
What other stocks do shareholders of Masimo own?
Who are Masimo's key executives?
Masimo's management team includes the folowing people:
- Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 54)
- Mr. Micah Young, Exec. VP of Fin. & CFO (Age 40)
- Mr. Anand Sampath, Chief Operating Officer (Age 53)
- Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 74)
- Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 46)
Who are Masimo's major shareholders?
Masimo's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.52%), FMR LLC (7.34%), MERIAN GLOBAL INVESTORS UK Ltd (1.47%), American Century Companies Inc. (1.41%), Victory Capital Management Inc. (1.37%) and Bank of New York Mellon Corp (1.13%). Company insiders that own Masimo stock include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Raad Mark De, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo.
Which major investors are selling Masimo stock?
MASI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Two Sigma Investments LP, D. E. Shaw & Co. Inc., American Century Companies Inc., Prudential Financial Inc., Assenagon Asset Management S.A. and Bank of Nova Scotia. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Insider Buying and Selling for Masimo.
Which major investors are buying Masimo stock?
MASI stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Norges Bank, Fundsmith LLP, Lord Abbett & CO. LLC, Scout Investments Inc., First Trust Advisors LP, Ownership Capital B.V. and MERIAN GLOBAL INVESTORS UK Ltd. View Insider Buying and Selling for Masimo.
How do I buy shares of Masimo?
Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Masimo's stock price today?
One share of MASI stock can currently be purchased for approximately $133.60.
How big of a company is Masimo?
Masimo has a market capitalization of $7.10 billion and generates $858.29 million in revenue each year. The medical equipment provider earns $193.54 million in net income (profit) each year or $3.03 on an earnings per share basis. Masimo employs 1,500 workers across the globe.
What is Masimo's official website?
How can I contact Masimo?
Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at ekammerma[email protected]
MarketBeat Community Rating for Masimo (NASDAQ MASI)
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
